SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday December 3, at 6:10 a.m. PT / 9:10 a.m. ET in Miami, Florida.
A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at and will be archived there for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir Biotechnology's clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and programs across several clinically validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Media
Arran Attridge
Senior Vice President, Corporate Communications
aattridge@vir.bio
Investors
Richard Lepke
Senior Director, Investor Relations
rlepke@vir.bio
Source: Vir Biotechnology, Inc. 舊金山--(業務線)-- vir biotechnology公司(納斯達克:VIR)今天宣佈,執行總裁Marianne De Backer萬.Sc.、博士、工商管理碩士,將於12月3日星期二上午6:10參加第7屆Evercore ISI HealthCONx會議的爐邊聊天,在佛羅里達州邁阿密舉行。
爐邊聊天的現場網絡直播將在vir biotechnology網站的投資者部分的活動和演示中提供,並將在那裏存檔30天。
關於Vir Biotechnology,Inc。
vir biotechnology公司是一家臨床階段的生物製藥公司,專注於通過發現和開發治療嚴重傳染病和癌症的藥物,激發免疫系統以改變生活。vir biotechnology的臨床階段組合包括慢性丙型肝炎和慢性乙型肝炎感染的傳染病項目,以及實體瘤適應症中幾個臨床驗證靶點的項目。vir biotechnology還擁有一系列涵蓋各種傳染病和腫瘤惡性腫瘤的臨床前項目組合。vir biotechnology定期在其網站上發佈對投資者可能重要的信息。
媒體
Arran Attridge
公司通信-半導體高級副總裁
aattridge@vir.bio
投資者聯繫
Richard Lepke
投資者關係高級董事
rlepke@vir.bio
來源:Vir Biotechnology,Inc.